Li Yan-Fei, Peng Tao, Duan Ran-Ran, Wang Xiao-Han, Gao Hui-Li, Wang Jing-Tao, Teng Jun-Fang, Jia Yan-Jie
Department of Neurology, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Zhongguo Dang Dai Er Ke Za Zhi. 2014 Jun;16(6):629-33.
To screen out differentially expressed microRNAs (miRNAs) in the plasma of children with methylmalonic acidemia (MMA), to determine the expression of miR-9-1 in plasma and to preliminarily evaluate the significance of miR-9-1 as a biomarker in MMA.
Plasma was obtained from 17 MMA children, 10 hyperhomocysteinemia (HHcy) children without MMA (HHcy group), and 10 normal controls. Of 17 MMA children, 12 had HHcy (MMA+HHcy group), and 5 had no HHcy (MMA group). The differentially expressed miRNAs were screened out by miRNA microarray. Differentially expressed miR-9-1 was selected, and plasma miR-9-1 levels were determined by RT-PCR. Urine was collected from MMA patients who received vitamin B12 treatment, and plasma miR-9-1 levels were determined by RT-PCR after treatment.
The miRNA microarray analysis showed that 26 miRNAs were differentially expressed, among which 16 miRNAs (including miR-9-1) were down-regulated over 2 times, while 10 miRNAs were up-regulated over 2 times. The MMA+HHcy , MMA and HHcy groups had significantly down-regulated miR-9-1 compared with the normal control group (P<0.01). The patients who showed a good response to vitamin B12 treatment had significantly increased plasma miR-9-1 levels, without significant difference compared with the normal control group.
Plasma miR-9-1 is significantly down-regulated in MMA patients, but it is significantly up-regulated after vitamin B12 treatment, suggesting that miR-9-1 may act as a biomarker in monitoring the progression of MMA.
筛选甲基丙二酸血症(MMA)患儿血浆中差异表达的微小RNA(miRNA),检测miR-9-1在血浆中的表达,并初步评估miR-9-1作为MMA生物标志物的意义。
收集17例MMA患儿、10例无MMA的高同型半胱氨酸血症(HHcy)患儿(HHcy组)及10例正常对照者的血浆。17例MMA患儿中,12例伴有HHcy(MMA+HHcy组),5例无HHcy(MMA组)。采用miRNA芯片筛选差异表达的miRNA。选取差异表达的miR-9-1,通过逆转录聚合酶链反应(RT-PCR)检测血浆miR-9-1水平。收集接受维生素B12治疗的MMA患者的尿液,治疗后通过RT-PCR检测血浆miR-9-1水平。
miRNA芯片分析显示,有26个miRNA差异表达,其中16个miRNA(包括miR-9-1)下调超过2倍,10个miRNA上调超过2倍。与正常对照组相比,MMA+HHcy组、MMA组和HHcy组的miR-9-1均显著下调(P<0.01)。维生素B12治疗反应良好的患者血浆miR-9-1水平显著升高,与正常对照组相比无显著差异。
MMA患者血浆miR-9-1显著下调,但维生素B12治疗后显著上调,提示miR-9-1可能作为监测MMA病情进展的生物标志物。